8-K: Senseonics Reports 22% Revenue Growth in Q1 2024, Achieves iCGM Designation

Senseonics Holdings, Inc. announced a 22% year-over-year revenue increase in the first quarter of 2024, along with key advancements in their Eversense CGM system.

Summary

• Senseonics reported a total revenue of $5.1 million for the first quarter of 2024, a 22% increase compared to $4.1 million in the same period last year.
• U.S. revenue reached $3.7 million, up from $2.1 million year-over-year, while revenue outside the U.S. was $1.4 million, compared to $2.0 million in the prior year period.
• The company's gross profit for the quarter was $0.3 million, down from $0.4 million in the first quarter of 2023, primarily due to increased fixed manufacturing costs.
• Sales, marketing, and general and administrative expenses increased by $0.4 million to $8.1 million, driven by marketing initiatives.
• Research and development expenses decreased by $2.0 million to $10.4 million due to the completion of the ENHANCE pivotal trial.
• Senseonics reported a net loss of $18.9 million, or $0.03 per share, compared to a net income of $1.3 million, or $0.00 per share, in the first quarter of 2023, with the decrease primarily due to accounting for embedded derivatives, fair value adjustments and the exchange of a portion of the 2025 notes.
• The company maintains its outlook for first half 2024 global net revenue to be $10 million, representing approximately 16% growth compared to the first half of 2023.

Sentiment

Score: 5

Explanation: The document presents mixed results. While there is positive revenue growth and key product advancements, the significant net loss and decrease in gross profit temper the overall sentiment. The company is making progress but faces financial challenges.

Positives

• The company experienced a significant 22% increase in revenue compared to the same quarter last year.
• The Eversense system received iCGM designation from the FDA, a key milestone for integration with insulin pumps.
• The collaboration with Mercy health care system is expected to enhance patient outcomes and reduce healthcare costs.
• The filing of the 510(k) submission for the 365-day system is a positive step for future product development.
• The company is maintaining its revenue outlook for the first half of 2024, projecting 16% growth.

Negatives

• Gross profit decreased to $0.3 million from $0.4 million in the same quarter last year due to increased fixed manufacturing costs.
• The company reported a net loss of $18.9 million, a significant decrease compared to a net income of $1.3 million in the first quarter of 2023.
• Revenue outside the U.S. decreased to $1.4 million from $2.0 million in the prior year period.

Risks

• The company's financial results are subject to uncertainties in the commercialization of the Eversense product.
• There are risks associated with the integration and commercial terms with new partners and third parties.
• The company faces uncertainties in insurer, regulatory, and administrative processes and decisions.
• The current economic environment poses risks to the company's financial performance.
• The company's future performance is subject to the risk factors detailed in their SEC filings.

Future Outlook

Senseonics expects first half 2024 global net revenue to be $10 million, representing approximately 16% growth compared to the first half of 2023. The company plans to provide its full year financial outlook at an investor event during the American Diabetes Association Scientific Sessions in June 2024.

Management Comments

• Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that it has been a very productive start to the year for Senseonics as they continue to expand the features of Eversense to benefit more people with diabetes.
• Tim Goodnow also mentioned that the Eversense platform now sits in its strongest position ever, following receipt of the iCGM designation, the filing of their next-generation 365-day system with the FDA, and the announcements of their Eversense RPM and collaboration with Mercy.
• The CEO expressed confidence that Eversense can help improve patient outcomes and lower the cost of care for the thousands of patients in the Mercy system who could benefit from CGM.

Industry Context

The announcement highlights Senseonics' progress in the competitive CGM market, particularly with the iCGM designation and the development of a longer-lasting 365-day system. The collaboration with Mercy health care system demonstrates a move towards integrating CGM technology into broader healthcare management programs, which is a growing trend in the industry.

Comparison to Industry Standards

• Senseonics' 22% revenue growth is a positive sign, but it is important to compare this to the growth rates of competitors like Dexcom and Abbott, who are leaders in the CGM market.
• The iCGM designation is a significant achievement, placing Senseonics in a position to compete with other integrated CGM systems.
• The collaboration with Mercy is a strategic move, similar to other partnerships between medical device companies and healthcare providers, but the impact on revenue and market share will need to be monitored.
• The decrease in gross profit due to increased manufacturing costs is a concern, and it will be important to see how Senseonics manages these costs compared to industry benchmarks.
• The net loss of $18.9 million is a significant concern and needs to be compared to the profitability of other companies in the medical device sector.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and product advancements.
• Employees may be impacted by the company's financial performance and future growth plans.
• Customers may benefit from the improved Eversense system and the integration with healthcare providers.
• Suppliers may be affected by the company's manufacturing costs and production volumes.
• Creditors may be concerned about the company's net loss and debt levels.

Next Steps

• The company plans to provide its full year financial outlook at an investor event during the American Diabetes Association Scientific Sessions on June 21-24, 2024.
• Senseonics will continue to work on the commercialization of the Eversense product and the expansion of the Eversense product and a new RPM solution.
• The company will continue to pursue regulatory approvals for its next-generation 365-day system.

Key Dates

Keywords

Eversense, CGM, Continuous Glucose Monitoring, Diabetes, iCGM, FDA, Revenue, Medical Technology, Implantable Sensor, Remote Patient Monitoring